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Aims Elderly heart failure (HF) patients are assumed to prefer improved quality of life over longevity, but sufficient data are




At baseline and after 12 and 18 months, 622 HF patients aged ≥60 years (77+8 years, 74% NYHA-class ≥III) par-
ticipating in the Trial of Intensified vs. standard Medical therapy in Elderly patients with Congestive Heart Failure had
prospective evaluation of end-of-life preferences by answering trade-off questions (willingness to accept a shorter life
span in return for living without symptoms) and preferences for resuscitation if necessary. The time trade-off ques-
tion was answered by 555 patients (89%), 74% of whom were not willing to trade survival time for improved QoL.
This proportion increased over time (Month 12: 85%, Month 18: 87%, P, 0.001). In multivariable analysis, willingness
to trade survival time increased with age, female sex, a reduced Duke Activity Status Index, Geriatric Depression
Score, and history of gout, exercise intolerance, constipation and oedema, but even combining these variables
did not result in reliable prediction. Of 603 (97%) patients expressing their resuscitation preference, 51% wished
resuscitation, 39% did not, and 10% were undecided, with little changes over time. In 430 patients resuscitation
orders were known; they differed from patients’ preferences 32% of the time. End-of-life preferences were not
correlated to 18-month outcome.
Conclusion Elderly HF patients are willing to address their end-of-life preferences. The majority prefers longevity over QoL and
half wished resuscitation if necessary. Prediction of individual preferences was inaccurate. Trial Registration: isrctn.org
Identifier: ISRCTN43596477
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Asking patients about expectations and preferences regarding
treatment is increasingly recognized as an important element in
patient care.1 This is particularly true for patients with chronic ill-
nesses, in whom full recovery is not possible, but in whom
quality-of-life (QoL) is considered a valuable goal of therapy. In
chronic heart failure (CHF), several treatment modalities targeting
different outcomes have become available. Some treatments
improve both symptoms and prognosis. Some, such as inotropic
agents or opioids, specifically focus on symptom relief, even at
the expense of survival. And some focus only on prognosis, such
as internal cardioverter-defibrillators (ICD) that reduce sudden
cardiac death but do not affect symptoms and may even increase
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the number of CHF-related hospitalizations.2 Although negative
effects may be reduced by combining ICD with cardiac resynchro-
nization in selected patients,3 the question arises if pure reduction
in mortality is the primary goal in all CHF patients or if patients
would prefer symptom relief to survival.
This question is especially relevant since the average CHF
patient is of advanced age with multiple co-morbidities.4 Intuitively,
it may be assumed that particularly elderly patients with severe
symptomatic chronic disease would prefer a better QoL to pro-
longed survival. A significant proportion of younger patients
were willing to trade survival time for perfect health.5,6 Still, the as-
sumption that older patients are more willing to trade survival time
for QoL might be wrong, as sicker patients can express stronger
preferences for life-prolonging treatments compared with health-
ier people.7 Data giving insight into end-of-life preferences in
elderly CHF patients, however, are lacking. Therefore, we aimed
to investigate end-of-life and cardiopulmonary resuscitation
(CPR) preferences in elderly CHF patients. In addition, predictive
factors for willingness to trade survival time for better QoL and
for wanting resuscitation if necessary were evaluated.
Methods
Setting and participants
Patients participating in the Trial of Intensified vs. standard Medical therapy
in Elderly patients with Congestive Heart Failure (TIME-CHF; n ¼ 622)
were included in the analysis as described previously.4,8 In short,
TIME-CHF was a prospective randomized controlled multicentre trial
addressing the management of elderly patients with CHF comparing a
standard symptom-guided therapy with an intensified, N-terminal-
pro-B-type natriuretic peptide (NT-BNP) guided medical therapy.
Patients aged ≥60 years, with symptomatic CHF (NYHA ≥II), a
history of CHF hospitalization within the last year, and a NT-BNP
level .2× the upper limit of normal were included and stratified
into two age groups, i.e. 60–74 years (n ¼ 242, mean age 69+4
years) and ≥75 years (n ¼ 380, mean age 82+4 years). Some exclu-
sion criteria applied,4 but on average, the patients were similar to those
included in large registries.9,10 The ethics committee of each centre
approved the study and each patient gave written informed consent
for participation.
Baseline assessment included medical history, signs, and symptoms
of CHF, QoL, and end-of-life preference questionnaires, laboratory
results, and the 6 min walk test.
Quality of life was measured by structured, self-administered ques-
tionnaires [Minnesota Living with CHF (MLwHF),11 Duke Activity
Status Index (DASI),12 and short form of the IQOLA SF-36
(SF-12)13]. Furthermore, Geriatric Depression Scale short form
(GDS)14 and the Hodkinson abbreviated mental test15 were used.
Outcomes
End-of-life preferences were assessed by using a time trade-off (TTO)
tool6 and one question concerning CPR preference (yes, no, un-
decided). Both instruments were administered verbally after a descrip-
tive introduction. Cardiopulmonary resuscitation preference was asked
after explaining meaning and circumstances of CPR. To assess TTO,
patients were asked whether they preferred living 2 years in their
current state of health or living 1 year in excellent health. If 1 year
in excellent health was chosen, the patients were asked whether
they would prefer 2 years in their current state of health or
6 months in perfect health. If 2 years in the current state were
chosen, then they were asked whether they would prefer 2 years in
their current state of health or 18 months in perfect health. The
series was continued until the point at which the choices were equiva-
lent. This time point subtracted from 24 months yielded the number of
months of survival time that the patient would be willing to trade.6
End-of-life preferences were assessed at baseline, and at 12 and 18
months. In addition, CPR order during last hospitalization was assessed
in patients who were included presently after discharge.
Statistical analysis
Results are shown as mean (SD), median (IQR), and numbers and per-
centages as appropriate. Patients were divided into four groups: not
willing to trade any survival time, willing to trade ≤6 months,
.6–12 months, and .12 months. Group comparisons were done
using independent t-test, Mann–Whitney U-test, or Fisher’s exact
test, as appropriate. Multivariable analysis was done using logistic re-
gression with stepwise backward procedure (inclusion P ≤ 0.05, exclu-
sion P. 0.1), including variables shown in Table 1. No imputation for
missing data was performed. Changes over time were assessed by
using Wilcoxon signed ranks and Friedman’s ANOVA, as appropriate,
using Bonferroni adjustment where required. Adjusting results for
participating centres did not significantly influence results. Therefore,
unadjusted analyses are presented. A two-sided P-value of 0.05 or
less was considered to be statistically significant. Calculations were
done using the commercially available statistical package SPSS 15.0.
Results
Baseline characteristics are shown in Table 1. Patients were elderly,
severely symptomatic, and most had reduced left-ventricular sys-
tolic function (LVEF; 80% with LVEF≤45%). Most had significant
co-morbidities and QoL was considerably reduced. At baseline,
555 patients (89%) responded to the TTO question. Those not
responding had more dementia, more co-morbidities, worse
QoL, higher depression score, worse mental test, poorer results
from the 6 min walk test, and lower haemoglobin levels
(Table 1). During follow-up, the proportion of patients not answer-
ing the TTO interview increased [Month 12: 17% of patients alive
(n ¼ 81); Month 18: 16% (n ¼ 70)]. Overall, 595 (96%) of the
patients replied at least once to the TTO question. Of these,
32% (n ¼ 190) expressed some willingness to accept a reduced
survival time for better QoL on at least one occasion.
Willingness to trade survival time
At baseline, 74% of the patients were not willing to trade any sur-
vival time for excellent health (Figure 1A). Of the remaining
patients, approximately equal groups were willing to trade up to
6 months, .6 months to 1 year, or more than 1 year. Patients
aged ≥75 years were slightly more likely to be willing to trade
than younger patients (29 vs. 20%, P ¼ 0.01), whereas the propor-
tion not responding to this question did not differ between the age
groups (11% in both).
During follow-up, the proportion of patients willing to trade any
survival time decreased (Month 12: n ¼ 62 of 401, Month 18: n ¼
48 of 368, Figure 2, P, 0.01), with no differences between age
groups. When considering all patients not responding to the ques-
tion at Month 12 or withdrawing consent prior to this visit as
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willing to trade any survival time, the proportion of those not
willing to trade would still be 72% (at Month 18, 75%).
Of the original 622 patients, 376 (60%) replied to the TTO
question both at baseline and at Month 12 [117 (19%) died, 52
(8%) withdrew consent, 77 (12%) replied at only one time
point]. Of these, the response was the same at both visits in 280
(75%) patients, with 263 (94%) not willing to trade any survival
time (Table 2). A comparable picture was seen comparing the
339 patients who responded at both Months 12 and 18: no
change in 280 (83%) patients, 22 (6%) patients with more, and
37 (11%) patients with less willingness to trade survival time, but
the changes over time were no longer statistically significant
(P ¼ 0.18). Surviving patients replying only once to the question
did not differ significantly from the others (data not shown).
Predictors of willingness to trade
Patients indicating any willingness to trade survival time for
symptom-free living differed in many ways from those unwilling
to trade. They were older, more often female, lived more often
on their own and/or were not married, had more signs and symp-
toms of CHF and poorer QoL. A history of selected co-
morbidities was also related to willingness to trade (Table 3).
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Not expressing EoL preferences
(n5 67)
P-value
Female sex 253 (41%) 229 (41%) 24 (36%) 0.43
Age (years) 76.9 + 7.6 76.8 + 7.5 78.0 + 7.8 0.19
BMI (m2/kg) 25.6 + 4.4 25.7 + 4.4 25.0 + 4.9 0.28
Cause of HF 0.46
CAD 330 (53%) 297 (54%) 33 (49%)
DCM 89 (14%) 79 (14%) 10 (15%)
HHD 173 (28%) 155 (28%) 18 (27%)
Other 30 (5%) 24 (4%) 6 (9%)
LVEF (%) 35.0 + 13.0 34.9 + 12.8 35.8 + 14.7 0.60
LVEF .45% 123 (20%) 108 (19%) 15 (22%) 0.62
Hypertension 462 (74%) 410 (74%) 52 (78%) 0.56
Diabetes 222 (36%) 197 (36%) 25 (37%) 0.79
CVI/TIA 98 (16%) 86 (16%) 12 (18%) 0.60
Chronic obstructive pulmonary
disease
124 (20%) 104 (19%) 20 (30%) 0.04
PAOD 124 (20%) 108 (20%) 16 (24%) 0.42
Cancer 86 (14%) 76 (14%) 10 (15%) 0.71
Dementia 28 (5%) 19 (3%) 9 (13%) 0.001
Depression 79 (13%) 70 (13%) 9 (13%) 0.85
Renal failure 355 (57%) 314 (57%) 41 (61%) 0.52
≥2 co-morbidities 459 (74%) 402 (72%) 57 (85%) 0.03
NYHA-class ≥III 473 (76%) 420 (76%) 53 (79%) 0.80
Angina 126 (21%) 108 (20%) 18 (28%) 0.14
6 m WT good effort 492 (79%) 453 (82%) 39 (58%) ,0.001
Systolic blood pressure 122 + 20 122 + 20 122 + 21 0.87
Heart rate 76 + 14 75 + 14 77 + 14 0.38
Creatinine 116 + 38 115 + 37 120 + 50 0.52
Haemoglobin 131 + 18 131 + 18 127 + 17 0.06
NT-BNP (pg/mL) 3836 (1916–6905) 3749 (1892–6847) 4165 (2338–8212) 0.25
DASI 7.2 (1.8–15.4) 7.2 (2.7–15.5) 4.5 (0.0–7.3) 0.001
Minnesota LHFQ 40 (25–55) 39 (25–54) 44 (34–61) 0.04
SF-12 physical 32 (26–39) 33 (27–40) 29 (22–36) 0.004
SF-12 mental 46 (378–55) 46 (37–56) 42 (33–52) 0.1
GDS 4 (2–6) 4 (2–6) 4 (3–8) 0.02
Hodkinson MT 9 (9–10) 10 (9–10) 9 (7–10) ,0.001
EOL, end-of-life; CAD, coronary artery disease; DCM, dilated cardiomyopathy; HHD, hypertensive heart disease; LVEF, left-ventricular ejection fraction; CVI/TIA, cerebrovascular
insult or transient ischaemic attack; PAOD, peripheral arterial occlusive disease; 6 m WT, 6 min walk test; DASI, Duke Activity Status Index; LHFQ, Minnesota Living with Heart
Failure Questionnaire; GDS, Geriatric Depression Score; MT, mental test.
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During follow-up, spouse of four patients died with little effect on
end-of-life preferences.
Overall, 15 patients (2.4%) of the total study population had an
ICD implanted, all of them were not willing to trade (P ¼ 0.03).
Because of the small number of patients with ICD, this was not
considered in multivariable analysis.
In multivariable analysis, the following parameters were predict-
ive of willingness to trade survival time: age [OR ¼ 1.54 per
10 years, 95% confidence interval (CI) 1.13–2.10], reduced DASI
(OR ¼ 1.04 per score point, 95% CI 1.01–1.06), history of gout
(OR ¼ 2.40, 95% CI 1.22–4.70), female gender (OR ¼ 1.74, 95%
CI 1.12–2.72), GDS (OR ¼ 1.10 per score point, 95% CI 1.02–
1.18), exercise intolerance (OR ¼ 1.43 per class on scale 0–3,
95% CI 1.08–1.89), constipation (OR ¼ 1.23 per class on scale
0–3, 95% CI 1.01–1.50), and history of oedema (OR ¼ 1.24 per
class on scale 0–3, 1.01–1.52). The c-statistic of this multivariable
logistic regression model was 0.710 (95% CI 0.657–0.763). The
best cut-off was a probability of 33%, separating patients into
those with a high (n ¼ 117) and a low (n ¼ 404) likelihood to
accept a shorter survival time. However, even in the ‘high likeli-
hood’ group, more than half of the patients (52%) preferred lon-
gevity vs. 83% in the low likelihood group (P, 0.001).
Figure 1 (A) Willingness to trade survival time for better health in the patient population replying to the time trade-off questions. Left column
all patients (n ¼ 555), middle column patients ,75 (n ¼ 216), and right column ≥75 years of age (n ¼ 339). (B) Preference for cardiopulmon-
ary resuscitation at baseline in the patient population replying to this question. Left column all patients (n ¼ 603), middle ,75 (n ¼ 234) and
right ≥75 years of age (n ¼ 369).
Figure 2 Changes in willingness to trade survival time (left) and
not wanting resuscitation (right) over time. *P, 0.01 compared
with baseline.
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Table 2 Willingness to trade survival time for













No trade 263 11 9 8
,6 months 16 3 – 2
6 m–1 year 21 1 6 4
.1 year 17 2 5 8
Willingness to trade survival time for freedom of symptoms. Bold, unchanged (n ¼
280, 75%); italic, more willing to trade at Month 12 (n ¼ 30, 8%); normal font, less
willing to trade at Month 12 (n ¼ 62, 17%).
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Table 3 Comparison of patients willing and not-willing to trade survival time for quality of life
Willing to trade (n5 143) Not-willing to trade (n5 412) P-value
Age 78.7 + 7.6 76.1 + 7.4 0.001
Female sex 78 (55%) 151 (37%) ,0.001
LVEF (%) 38 + 13 34 + 12 0.003
LVEF .45% 36 (25%) 72 (17%) 0.05
Main diagnosis 0.44
CAD 73 (51%) 224 (54%)
DCM 16 (11%) 63 (15%)
HHD 48 (34%) 107 (26%)
Other 6 (4%) 18 (5%)
Medical history
Diabetes 56 (39%) 141 (34%) 0.31
CVI/TIA 20 (14%) 66 (16%) 0.60
Chronic obstructive pulmonary disease 30 (21%) 74 (18%) 0.46
PAOD 25 (17%) 83 (20%) 0.54
Cancer 20 (14%) 56 (14%) 0.89
Osteoporosis 23 (16%) 36 (9%) 0.02
Depression 26 (18%) 44 (11%) 0.03
Renal failure 78 (55%) 236 (57%) 0.63
Gout 20 (14%) 29 (7%) 0.02
Arthritis 43 (30%) 107 (26%) 0.38
Charlson Score 3 (2–4) 3 (2–4) 0.70
NYHA class (II/III/IV) 25/92/26 (17%/64%/18%) 110/251/51 (27%/61%/12%) 0.01
Angina (yes) 36 (26%) 72 (18%) 0.05
Orthopnea (0–3) 43/45/43/12 (30/32/30/8%) 136/158/80/38 (33/38/19/9%) 0.07
Oedema (0–3) 58/35/23/25 (41/25/16/18%) 234/84/56/37 (57/20/14/9%) 0.001
Ex. intolerance (0–3) 6/29/66/38 (4/21/48/27%) 38/128/177/68 (9/31/43/17%) 0.001
Constipation (0–3) 88/23/7/25 (62/16/5/17%) 314/38/24/33 (77/9/6/8%) 0.001
Clinical examination
Rales (0–3) 62/55/21/5 (43/38/15/4%) 240/120/41/11 (58/29/10/3%) 0.006
Jugular vein (0–3) 50/34/35/20 (36/25/25/14%) 160/114/74/58 (39/28/18/14%) 0.32
Syst. BP (mmHg) 121 + 19 122 + 20 0.48
Heart rate rest (bpm) 78 + 14 75 + 14 0.03
NT-BNP (pg/mL) 3926 (1792–7089) 3654 (1904–6740) 0.63
Creatinine (mmol/L) 113 + 37 116 + 37 0.45
Haemoglobin (g/L) 127 + 19 132 + 18 0.003
6 min walk distance (m) 230 + 112 277 + 122 0.001
QoL/social status
DASI 7.2 (0.0–15.2) 7.2 (2.8–15.5) 0.05
Minnesota LHFQ 41 (28–57) 39 (24–54) 0.10
SF-12 physical 30 (25–37) 34 (27–40) 0.001
SF-12 mental 45 (38–53) 46 (37–56) 0.60
GDS 4 (2–7) 3 (2–6) 0.002
Hodkinson MT 10 (9–10) 10 (9–10) 0.82
Married 68 (48%) 239 (58%) 0.03
Not alone 73 (51%) 268 (65%) 0.004
For abbreviations, see Table 1.
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Resuscitation preferences
Most patients (n ¼ 603, 97%) responded to the resuscitation ques-
tion. At baseline, approximately one-third did not want CPR
(Figure 1B). Age-influenced preference for CPR to a limited
extent only (Figure 1B, P, 0.001).
The proportion not wanting resuscitation increased slightly over
time (Figure 2, change over time P ¼ 0.01). Figure 3 depicts a com-
parison of the CPR preference at baseline and after 12 months
(P ¼ 0.49). At Month 18, compared with baseline, 238 patients
out of 381 (62%) did not change their preference, 56 (15%)
changed to wanting CPR, and 87 (23%) changed to not wanting
CPR (P, 0.01). From the 15 patients with ICD implanted, 11
(73%) wanted to receive CPR (P ¼ 0.09). Surviving patients reply-
ing only once to the question did not differ significantly from the
others (data not shown).
Multivariable factors predictive for resuscitation preference
were younger age (OR ¼ 0.47 per each 10 year increase, 95% CI
0.28–0.78), male sex (OR ¼ 2.13, 95% CI 1.42–3.19), lower
GDS (OR ¼ 0.92 per each score point increase, 0.86–0.97),
being married (OR ¼ 1.67, 95% CI 1.14–2.46), less orthostatic re-
sponse (OR ¼ 0.71 per class on scale 0–3, 95% CI 0.55–0.92),
higher LVEF (OR ¼ 1.19 per 10% increase, 95% CI 1.02–1.38),
no history of anaemia (OR ¼ 0.64, 95% CI 0.43–0.97), and
history of syncope (OR ¼ 2.16, 95% CI 1.05–4.42). Again, predic-
tion of patients’ preference was relatively inaccurate [c-statistic
0.741 (95% CI 0.700–0.782)].
Resuscitation preferences in relation to
resuscitation orders
A total of 481 patients (77%) were included in the study presently
after discharge from hospital. Of these, both CPR preferences at
study entry and CPR orders from pre-randomization hospitaliza-
tion were known for 430 patients (89%). For 390 patients with dis-
tinct CPR preferences, patient preferences (as answered to the
study question) differed from the hospital records 32% of the
time (n ¼ 126; Figure 4). No predictors for disagreement could
be identified (data not shown).
Relation of willingness to trade and
wishing cardiopulmonary resuscitation
with mortality
During follow-up, 20% of the patients died (Table 4). There were
no significant differences in either all-cause mortality or cardiovas-
cular mortality in relation to patients’ willingness to trade survival
time or wish to be resuscitated if necessary. However, non-
cardiovascular deaths were more common in patients willing to
trade survival time, with a similar trend in patients not wanting re-
suscitation (Table 4). No significant interaction with age or age
group (, or ≥75 years) was seen.
Figure 4 Comparison of preference for cardiopulmonary re-
suscitation and cardiopulmonary resuscitation orders at baseline
(shaded ¼ disagreement between cardiopulmonary resuscitation
order and patient’s preference).
Figure 3 Comparison of cardiopulmonary resuscitation prefer-
ence at baseline and at Month 12. Arrows indicate changes of in-
dividual patient preferences (numbers give number of patients).
Size of arrows is related to number of patients in each category.
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Table 4 Mortality rate depending on end-of-life preferences
Willing to trade survival time (n5 555) Wanting CPR (n5 603)
Yes (n5 143) No (n 5 412) P-value Yes (n 5 307) No/undecided (n5 296) P-value
All cause 33 (23%) 79 (19%) 0.33 58 (19%) 62 (21%) 0.54
CV 20 (14%) 68 (17%) 0.51 50 (16%) 44 (15%) 0.66
Non-CV 13 (9%) 11 (3%) 0.003 12 (3%) 14 (6%) 0.15
CV, cardiovascular.
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Discussion
Patient-centred decision making and open communication with
patients and their families are critical concepts in providing the
highest quality of care.16 This study addresses communication
issues and describes important new findings regarding end-of-life
preferences of elderly CHF patients with both reduced and pre-
served LVEF, exploring the willingness to trade survival time and
resuscitation preferences and changes over 18 months. It also cor-
related resuscitation preferences with resuscitation orders.
Most patients showed a high willingness to answer these difficult
questions, confirming previous findings.6,17,18 Importantly, the major-
ity preferred longevity over QoL, and half wished to be resuscitated if
necessary. This was also true in very old patients, although the rates of
willingness to trade in favour of longevity, and to be resuscitated,
decreased with age. To some extent, the findings of this study are
in contrast to the general belief19 and some previous findings5,20
that QoL is more important than longevity for elderly CHF patients,
but confirm recently published results in younger patients.6
Previous studies on health values have focused on seriously ill
patients,21 who often had cancer,22 were hospitalized,23 or were
living in a nursing home.24 In patients with CHF, the focus was
either on end-stage disease (e.g. patients confronted with cardiac
transplantation5), younger patients,6,20,23 or patients with various
chronic diseases.25 The vast majority of CHF patients, who are
elderly, however, have received little attention. These previous
studies found that health preferences may vary widely and may
change over time not only in relation to changes in health status.
The acceptability of a therapy which may result in reduced
health seems to increase with time and this increase seems more
likely in patients with a declining health status.25 This response
shift in relation to the disease trajectory inherent to the process
of accommodating an illness has been subject to specific
studies26 and seems particularly relevant to life-threatening dis-
eases. However, many of the previous studies25 focused on the ac-
ceptability of burdensome treatment rather than the preference of
longevity over QoL. With the availability of treatment to (solely)
improve prognosis, as in CHF, the latter question may be more
relevant. In fact, in the few patients having an ICD in our study, pre-
ferences were more in favour of longevity.
One possible explanation for the low willingness to trade sur-
vival time for better health may be that CHF patients tend to over-
estimate their life expectancy,27 which may result in favouring
more aggressive therapy.28 However, this applies to younger
patients, whereas patients with advanced age usually underestimate
their life expectancy.27 Given the high proportion of elderly
patients preferring longevity, it is unlikely that overestimating life
expectancy is the main explanation for our findings. In agreement
with previous results,6,29 the majority neither changed their willing-
ness to trade survival time nor their preference regarding CPR
over time. Still, there were patients who did change their prefer-
ences and these patients did not display characteristics that
would help to identify them.
Besides severity of CHF and related symptoms, age, female sex,
exercise intolerance, depression, and co-morbidities were relevant
predictors of end-of-life preferences. Patients with normal LVEF
showed more willingness to trade survival time, but this was
largely explained by age and sex. In addition, psychosocial factors
were relevant predictors. Other predictors, such as orthostatic re-
sponse or constipation, were less obvious, suggesting that individ-
ual perception may vary considerably. Moreover, combining these
characteristics did not allow for a reliable prediction. The findings,
therefore, emphasize the importance of asking and incorporating
the individual patient’s wishes into decision making, irrespective
of age, and to periodically repeat these discussions.16
The difficulty in communication is highlighted by the significant dis-
cordance between CPR orders and patients’ wishes, reinforcing
earlier findings that physicians’ perceptions of patients’ preferences
are not always accurate.29 Mismatches between preferences and
treatment were shown, especially in thedirectionof patients receiving
less aggressive care than they are willing to undergo30 or very old CHF
patients receiving more aggressive care than they desired.31 Insuffi-
cient communication about death and prognosis may partly be due
to physicians’ self-perceived inability to predict mortality in advanced
CHF,18 or their concerns that such discussions will destroy hope.17
This results in patients not receiving the treatment they prefer. Effect-
ive communication regarding end-of-life issues seems to rank among
the most important topics in patients with advanced CHF, resulting in
changes in preferences for life support.32 Thus, expecting death in the
near term should not detract from this discussion, but it should not be
postponed until patients are end-stage as patients seem to prefer
learning about their prognosis and its implications at a time of
optimal cognitive function.33
Limitations
There are limitations to such an assessment, the most important
being the hypothetical nature of the questions posed, which may
be particularly difficult for very old patients to understand, a
small proportion of which even having dementia, despite the fact
that these questionnaires have been validated and used with
success.5,6 Importantly, excluding patients having reduced mental
abilities as assessed by the Hodkinson abbreviated mental test
did not influence results (data not shown). The population
included in the study was primarily from middle European back-
grounds and cultural differences in patients’ willingness to engage
in discussion regarding end-of-life preferences were not examined,
limiting generalizability to patients from other socio-cultural back-
grounds. In addition, it is inherent to studies that the study sample
is selected and might not represent all patients. In particular, the
results may not apply to patients who are sicker when being
asked about their preferences. Still, as characteristics of our
study population were comparable to those of large cohort
studies,9,10 our study population seems to be representative of a
broad range of CHF patients.
Conclusion
Patients with CHF are willing to address their end-of-life prefer-
ences, often value longevity even at older age, but individual prefer-
ences are impossible to predict and may change over time,
reinforcing the value of listening to patients to provide relevant
insight and individualize care.34 Openness and communication
about prognosis, trajectories, and realistic treatment possibilities
engender hope and allow patients to plan for their future.17 This
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applies to various decisions that confront CHF patients, but may be
particularly important with respect to ICD implantation, turning off
the device, and treatment with purely symptomatic medical
therapy that may even reduce survival.
Funding
This study was sponsored by the Horten Research Foundation (Lugano,
Switzerland; .55% of the study’s budget), and by smaller unrestricted
grants from AstraZeneca Pharma, Novartis Pharma, Menarini Pharma,
Pfizer Pharma, Servier, Roche Diagnostics, Roche Pharma, and Merck
Pharma.
Conflict of interest: None declared.
Appendix
Steering committee of TIME-CHF: J. Beer, H. P. Brunner-La Rocca,
P. T. Buser, P. Dubach, P. Erne, W. Estlinbaum, P. Hilti, S. Osswald,
H. H. Osterhues, M. Peter, M. Pfisterer, P. Rickenbacher, H. Rickli,
M. M. Schieber, T. Suter, A. Vuillomenet, and S. I. Yoon.
TIME-CHF investigators see ref. 8.
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